Cara Q1 2022 Earnings Report
Key Takeaways
Cara Therapeutics reported a net loss of $27.7 million, or $(0.52) per basic and diluted share, for the first quarter of 2022. Total revenue was $4.8 million, and the company's cash, cash equivalents, and marketable securities totaled $209.6 million.
KORSUVA injection U.S. commercial launch began in April 2022 and is tracking to expectation.
Kapruvia approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients, triggering $15M milestone payment to Cara.
Top-line data from Phase 2 proof-of-concept trial of Oral KORSUVA in notalgia paresthetica expected in 2Q 2022.
Oral KORSUVA Phase 3 pruritus programs in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis underway.
Cara
Cara
Forward Guidance
Cara Therapeutics expects that its current unrestricted cash and cash equivalents and available-for-sale marketable securities, including the $15 million regulatory milestone payment earned in April 2022 upon European Commission approval of Kapruvia, will be sufficient to fund its currently anticipated operating expenses and capital requirements into the first half of 2024.